Shareholder Alert: Ademi LLP investigates whether Axonics, Inc. has obtained a Fair Price in its transaction with Boston Scientific

MILWAUKEE, Jan. 8, 2024 /PRNewswire/ -- Ademi LLP is investigating Axonics (Nasdaq: AXNX) for possible breaches of fiduciary duty and other violations of law in its transaction with Boston Scientific.

Click here to learn how to join the https://www.ademilaw.com/case/axonics-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.

In the transaction, Axonics stockholders will receive only $71 in cash per share, representing an equity value of approximately $3.7 billion. The transaction agreement unreasonably limits competing transactions for Axonics by imposing a significant penalty if Axonics accepts a competing bid. Axonics insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of Axonics' board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

If you own Axonics common stock and wish to obtain additional information, please contact Guri Ademi either at gademi@ademilaw.com or toll-free: 866-264-3995, or https://www.ademilaw.com/case/axonics-inc.

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-ademi-llp-investigates-whether-axonics-inc-has-obtained-a-fair-price-in-its-transaction-with-boston-scientific-302028501.html

SOURCE Ademi LLP